IRIDA is an autosomal recessive disorder caused by genetic mutations on TMPRSS6 gene which encodes Matriptase2 (MT2). An altered MT2 cannot appropriately suppress hepatic BMP6/SMAD signaling in case of low iron, hence hepcidin excess blocks dietary iron absorption, leading to a form of anemia resistant to oral iron supplementation. In this study, using the IRIDA mouse model Mask, we characterized homozygous (msk/msk) compared to asymptomatic heterozygous (msk/wt) mice, assessing the major parameters of iron status in different organs, at different ages in both sexes. The effect of carbonyl iron diet was analyzed as control iron supplementation being used for many studies in mice. It resulted effective in both anemic control and msk/msk mice, as expected, even if there is no information about its mechanism of absorption. Then, we mainly compared two forms of oral iron supplement, largely used for humans: Ferrous sulfate and Sucrosomial® Iron. In anemic control mice, the two oral formulations corrected hemoglobin levels from 11.40±0.60 to 15.38±1.71 g/dL in 2-4 weeks. Interestingly, in msk/msk mice, Ferrous sulfate did not increase hemoglobin likely due to ferroportin/hepcidin-dependent absorption, whereas Sucrosomial® Iron increased it from 11.50±0.60 to 13.53±0.64 g/dL mainly in the first week followed by a minor increase at 4 weeks with a stable level of 13.30±0.80 g/dL, probably because of alternative absorption. Thus, Sucrosomial® Iron, already used in other conditions of iron deficiency, may represent a promising option for oral iron supplementation in IRIDA patients. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.